Full-Time

Computational Clinical Scientist II

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$120k - $158kAnnually

Junior, Mid

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Bioinformatics
Computational Biology
Biology & Biotech
Required Skills
Python
Data Science
R
Requirements
  • MS. or Ph.D. in bioinformatics, biology, data science or a related field with emphasis on biological data analysis
  • 2+ years of pharmaceutical or biotech experience in bioinformatics focused on oncology, immunology, or related field
  • Proficiency and experience programming using R and/or Python
  • Proficiency in statistical models and analysis of clinical data. Some ML experience a strong plus.
  • Proficiency in visualizations and faceting of molecular data necessary (oncoplots, heatmaps, PCA, etc.)
  • Experience with efficacy, baseline demographic, and other outcome data generated in a clinical trial
  • Experience with statistical methods i.e. survival analysis, and causal inference
  • Expertise in bioinformatic analysis of cancer signaling pathways and driver mutations
  • Experience in tools to analyze cancer genomics data types (RNA, WES, ctDNA, etc) and common tool outputs (GATK, Salmon, OncoKB, VEP, etc.) preferred
Responsibilities
  • Integrate multiple data sources including circulating tumor DNA, patient enrollment data, molecular profiling (RNA/DNA sequencing outputs), multiplex immunohistochemistry to identify and validate new biomarkers for candidate drugs
  • Work with internal groups, contract research organizations and collaborators to deliver validated biomarker data and analysis
  • Support the development of biomarker related aspects of the trial design where bioinformatic analysis is required, including study protocols, lab manuals, clinical study reports, and other regulatory documents
  • Work with biomarker scientists to support analysis of biomarker readouts (summary statistics, and visualization of efficacy in molecular subgroups)
  • Collaborate with preclinical bioinformaticians to design, analyze and interpret experiments to validate biomarkers, understand compound mechanism of action, and identify biomarkers for patient selection and target engagement

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?